Sophia Genetics, a Swiss Medtech company, raised $110 Million in a series F financing round which was led by an Israeli venture capital firm aMoon, an Israel based life sciences venture capital firm. So Startup Nation even invests its money in Europe.
We’ve come a long way in Israel since the days when the country depended on every dime from tourism and the export of oranges.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Japan’s Hitachi Group co-led the round, which was also participated by Credit Suisse, Swisscom Ventures, Endeavour Vision, Generation Investment Management, and the Pictet group.
–
SOPHiA GENETICS Raises $110 Million in Oversubscribed New Funding Round #DataDrivenMedicine #PressRelease #Funding https://t.co/ZaYT9s2f9w pic.twitter.com/UKrKRZfCIV
— SOPHiA GENETICS (@SOPHiAGENETICS) October 1, 2020
SOPHIA GENETICS combines expertise in life sciences and medical disciplines with mathematical capabilities in data computing. Its stated mission is to bring data analytics solutions to market, to support healthcare professionals by maximizing the power of Data-Driven Medicine.
Yair Schindel, MD, Co-Founder & Managing Partner of the aMoon Fund, wrote on LinkedIn “SOPHiA GENETICS – incredible company, exceptional leadership! Jurgi Camblong & Troy Cox – On behalf of myself, Tomer Berkovitz and the entire aMoon Fund team, we’re honored to partner with you to help accelerate genomics globally for the benefit of patients and their families.”
“The overall demand for data-driven medicine is rapidly growing, and the next step is to successfully combine multiple sources of data to better address clinicians’ needs,” Dr. Tomer Berkovitz, Partner & CFO of aMoon said. “With this shift, more complex data will be generated, and we believe that SOPHIA’s decentralized model will play a pivotal role in empowering health organizations to offer better patient care.”
–
SOPHiA GENETICS – incredible company, exceptional leadership! Jurgi Camblong & Troy Cox – On behalf of myself, Tomer Berkovitz and the entire aMoon Fund team, we’re honored to partner with you to help accelerate genomics globally for the benefit of patien…https://t.co/pQLUBrmG5L
— Yair Schindel, MD (@YSchindel) October 1, 2020
